Loading...
Kinarus Therapeutics Holding AG
PRFN.SW•SIX
IndustrialsAirlines, Airports & Air Services
$0.04
$-0.00(-8.12%)
Kinarus Therapeutics Holding AG (PRFN.SW) Stock Overview
Explore Kinarus Therapeutics Holding AG’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for PRFN.SWStats details for PRFN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PRFN.SWAnalyst Recommendations details for PRFN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.
CEO
Mr. Jean-Claude Roch
Employees
15
Headquarters
Avenue de Florimont 3, Lausanne, VAUD
Founded
1999